CAPRICOR THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
CAPRICOR THERAPEUTICS, INC. (CAPR) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 17.75 million shares for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2025-11-10
- CAPRICOR THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 17.75M shares, a 14.84% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 17.70M shares, a 13.26% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 17.43M shares, a 11.22% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 15.45M shares, a 86.13% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2016 was 7.69M shares, a 23.38% increase from fiscal 2015.
- CAPRICOR THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2015 was 6.23M shares, a 17.42% increase from fiscal 2014.
- CAPRICOR THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2014 was 5.31M shares, a 1.68% increase from fiscal 2013.
- CAPRICOR THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2013 was 5.22M shares, a 3.56% decline from fiscal 2012.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-09-30 | 17.75M shares 10-Q · filed 2025-11-10 | 17.75M shares 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | 17.70M shares 10-Q · filed 2025-08-11 | 17.70M shares 10-Q · filed 2025-08-11 | ||||
| 2025-03-31 | 17.43M shares 10-Q · filed 2025-05-14 | |||||
| 2024-09-30 | 15.45M shares 10-Q · filed 2025-11-10 | 15.45M shares 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | 15.63M shares 10-Q · filed 2025-08-11 | 15.63M shares 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | 15.67M shares 10-Q · filed 2025-05-14 | |||||
| 2023-09-30 | 8.30M shares 10-Q · filed 2024-11-14 | 8.30M shares 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | 7.78M shares 10-Q · filed 2024-08-08 | 7.78M shares 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | 7.97M shares 10-Q · filed 2024-05-14 | |||||
| 2022-09-30 | 6.06M shares 10-Q · filed 2023-11-14 | 6.06M shares 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | 6.14M shares 10-Q · filed 2023-08-08 | 6.14M shares 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | 5.67M shares 10-Q · filed 2023-05-12 | |||||
| 2021-09-30 | 3.97M shares 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | 3.75M shares 10-Q · filed 2022-08-12 | |||||
| 2021-03-31 | 3.79M shares 10-Q · filed 2022-05-11 | |||||
| 2018-09-30 | 8.37M shares 10-Q · filed 2018-11-14 | 8.37M shares 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | 8.05M shares 10-Q · filed 2018-08-13 | |||||
| 2018-03-31 | 8.08M shares 10-Q · filed 2018-05-14 | |||||
| 2017-09-30 | 8.01M shares 10-Q · filed 2018-11-14 | 8.01M shares 10-Q · filed 2018-11-14 | ||||
| 2017-06-30 | 8.18M shares 10-Q · filed 2017-08-14 | 8.18M shares 10-Q · filed 2018-08-13 | ||||
| 2017-03-31 | 8.26M shares 10-Q · filed 2018-05-14 | |||||
| 2016-12-31 | 7.69M shares 10-K · filed 2017-03-16 | |||||
| 2016-09-30 | 7.53M shares 10-Q · filed 2017-11-14 | 7.53M shares 10-Q · filed 2017-11-14 | ||||
| 2016-06-30 | 7.73M shares 10-Q · filed 2017-08-14 | 7.73M shares 10-Q · filed 2017-08-14 | ||||
| 2016-03-31 | 7.20M shares 10-Q · filed 2017-05-15 | |||||
| 2015-12-31 | 6.23M shares 10-K · filed 2017-03-16 | |||||
| 2015-09-30 | 6.27M shares 10-Q · filed 2016-11-14 | 6.27M shares 10-Q · filed 2016-11-14 | ||||
| 2015-06-30 | 6.14M shares 10-Q · filed 2016-08-15 | 6.14M shares 10-Q · filed 2016-08-15 | ||||
| 2015-03-31 | 6.10M shares 10-Q · filed 2016-05-13 | |||||
| 2014-12-31 | 5.31M shares 10-K · filed 2016-03-30 | |||||
| 2014-09-30 | 5.31M shares 10-Q · filed 2015-11-13 | 5.31M shares 10-Q · filed 2015-11-13 | ||||
| 2014-06-30 | 5.19M shares 10-Q · filed 2015-08-14 | 5.19M shares 10-Q · filed 2015-08-14 | ||||
| 2014-03-31 | 5.04M shares 10-Q · filed 2015-05-13 | |||||
| 2013-12-31 | 5.22M shares 10-K · filed 2015-03-16 | |||||
| 2013-09-30 | 6.46M shares 10-Q · filed 2014-11-14 | 6.46M shares 10-Q · filed 2014-11-14 | ||||
| 2013-06-30 | 6.26M shares 10-Q · filed 2014-08-14 | 6.26M shares 10-Q · filed 2014-08-14 | ||||
| 2013-03-31 | 5.81M shares 10-Q · filed 2014-05-15 | 0.00 shares 10-Q · filed 2013-06-21 | ||||
| 2012-12-31 | 5.41M shares 10-K · filed 2014-03-31 | 0.00 shares 10-K · filed 2013-06-21 | ||||
| 2012-09-30 | 0.00 shares 10-Q · filed 2013-06-21 | |||||
| 2012-03-31 | 2.75M shares 10-Q · filed 2013-06-21 | |||||
| 2011-12-31 | 5.85M shares 10-K · filed 2013-06-21 | |||||
| 2011-09-30 | 5.79M shares 10-Q · filed 2013-06-21 | |||||
| 2011-06-30 | 5.79M shares 10-Q/A · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |